Injury to peripheral nerves often leads to abnormal pain states (hyperalgesia, allodynia and spontaneous pain), which can remain long after the injury heals. Although opioid agonists remain the gold standard for the treatment of moderate to severe pain, they show reduced efficacy against neuropathic pain. In addition to analgesia, opioid use is also associated with hyperalgesia and analgesia tolerance, whose underlying mechanisms share some commonalities with nerve injury-induced hypersensitivity.
| OPIOIDS AS ANALGESICS
Opioid receptors, mu (MOR), delta (DOR) and kappa (KOR), are G protein-coupled receptors that inhibit pain transmission at different levels of the ascending pain pathways, as well as at supraspinal areas related to pain integration (Ossipov et al., 2010; Stein & Machelska, 2011) . Opioid receptors also participate in inhibitory and facilitatory descending pathways mainly acting in periaqueductal grey (PAG) and rostral ventromedial medulla (RVM) (Fields, 2004; Ossipov et al., 2010) . Currently, available opioids produce their pharmacological effects mainly by activation of MOR (Matthes et al., 1996) and opioids used for pain are usually described as "mu agonists."
When opioids are given for pain treatment, analgesia usually appears associated with a wide range of possible side effects including constipation, nausea, vomiting, somnolence, mental clouding, respiratory depression and dysphoria or euphoria (Galanter, Kleber, & Brady, 2014) . Central opioid actions can also lead to analgesic tolerance and hyperalgesia. Due to their reinforcement properties, opioids have important abuse liability as revealed by the opioid | MARTÍNEZ-NAVARRO ET Al. abuse epidemics currently affecting the United States with dramatic consequences (NIDA, 2018) . Despite these severe side effects, their use in the management of severe pain is considered the standard of care (Rosenblum, Marsch, Joseph, & Portenoy, 2008) .
| LOW ANALGESIC EFFICACY OF OPIOIDS IN NEUROPATHIC PAIN
International guidelines for the treatment of neuropathic pain recommend as first-line therapy gabapentinoids (pregabalin and gabapentin) and tricyclic antidepressants or serotoninnoradrenaline reuptake inhibitors (amitriptyline and duloxetine) (Finnerup et al., 2015) . Based on the moderate analgesic efficacy in peripheral neuropathies of weak opioids, such as tramadol (Boureau, Legallicier, & Kabir-Ahmadi, 2003; Freeman et al., 2007; Norrbrink & Lundeberg, 2009; Sindrup et al., 2012) , these guidelines restrict its use to second-line therapy, in the same group than lidocaine and capsaicin patches (Finnerup et al., 2015) . Analgesic efficacy of strong opioids, such as morphine, fentanyl or oxycodone, in chronic neuropathic pain is still under considerable uncertainty. According to recent systematic reviews, controlled clinical trials provided low evidence of their efficacy and safety for chronic neuropathic pain (Cooper et al., 2017; Derry et al., 2016; Els et al., 2017; McNicol, Midbari, & Eisenberg, 2013; McNicol, Ferguson, & Schumann, 2017; Noble et al., 2010; Stannard et al., 2016) . Although some clinical trials reported significant efficacy (Gilron et al., 2005; Gimbel, Richards, & Portenoy, 2003; Hanna, O'Brien, & Wilson, 2008; Raja et al., 2002; Wu et al., 2008) , these results may be biased because of small sample size or short duration of treatment. Despite its moderate analgesic effect, therapeutic guidelines relegate strong opioids to third-line therapy in neuropathic pain, mainly because of safety concerns (Finnerup et al., 2015) .
First observations of low antinociceptive efficacy of systemic morphine in animal models of neuropathic pain emerged some decades ago (Idänpään-Heikkilä, Guilbaud, & Kayser, 1997; Kimura, Obata, & Saito, 2014; Obara, Przewlocki, & Przewlocka, 2004; Obara et al., 2007; Rashid, Inoue, Toda, & Ueda, 2004) . More recently, it has been shown that subchronic treatment with systemic morphine not only did not attenuate but may also aggravate cold and mechanical allodynia in nerve-injured mice (Roeckel et al., 2017) . Some authors argued that the reduced analgesic efficacy of systemic morphine may be due to a lack of functional spinal MOR following nerve injury, while the residual antinociceptive effect resulted from predominant supraspinal MOR activation (Bian, Nichols, Ossipov, Lai, & Porreca, 1995; Lee, Chaplan, & Yaksh, 1995) . This would explain why intracerebroventricular morphine produced dose-dependent antiallodynia, while intrathecal morphine was mostly ineffective in neuropathic pain conditions (Bian et al., 1995 (Bian et al., , 1999 Lee et al., 1995; Mao, Price, & Mayer, 1995; Ossipov, Lopez, Nichols, Bian, & Porreca, 1995a , 1995b ) except for one study (Suzuki, Chapman, & Dickenson, 1999) . Indeed, only opioids with a higher intrinsic activity on MOR than morphine, such as the peptides endomorphin 1 and 2, showed a relative effectiveness in alleviating neuropathic pain when administered intrathecally (Przewłocka, Mika, Labuz, Toth, & Przewłocki, 1999) . Slight differences of intrathecal morphine efficacy in neuropathic pain were also observed depending on the modality of nociceptive stimuli. Thus, morphine induced higher attenuation of heat (Wegert et al., 1997) and cold (Przewłocka et al., 1999) than mechanical hypersensitivity (Bian et al., 1995) . Due to the different mechanical (conveyed via myelinated Aδ fibres) and thermal (conveyed by unmyelinated C-fibres) nociceptive input-transmitting pathways, a possible explanation was that morphine affected them differently, since most MOR appear to be localized on C-fibres (Przewłocki & Przewłocka, 2001 ). Other researchers maintain that the low potency of systemic morphine in neuropathic pain is a consequence of the loss of peripheral components of its antinociceptive actions (Rashid et al., 2004) . These authors showed that morphine analgesic effect was unchanged when given by intracerebroventricular route, diminished when administered systemically or intrathecally, but almost completely lost following local peripheral (intraplantar) administration (Rashid et al., 2004) .
It also exists the opposite belief supporting the analgesic effectiveness of opioids acting at peripheral MOR under neuropathic pain conditions. Accordingly, intraplantar administration of morphine elicited moderate antinociception in neuropathic pain (Obara et al., 2004 (Obara et al., , 2007 Pertovaara & Wei, 2001 ). However, the half maximal effective dose (ED 50 ) of locally administered morphine required to induce analgesia in neuropathy was much higher than the ED 50 for other painful conditions, such as inflammatory pain (Obara et al., 2009 ). Interestingly, this was not the case of DOR agonists, which were reported to be effective in the same dose range in both pain models (Obara et al., 2009 ). In agreement with this peripheral MOR analgesia, systemic and local administration of peripherally restricted MOR agonists, such as loperamide or 14-O-methyl-oxymorphone derivatives, reversed mechanical and heat hypersensitivity of neuropathic rats in a dosedependent manner (Chung et al., 2012; Guan et al., 2008; Obara et al., 2007) . The same authors showed that the antihyperalgesic effect of systemic loperamide was blocked by systemic or intraplantar pre-treatment with methyl-naltrexone, a peripherally acting MOR antagonist (Guan et al., 2008) , although the DOR selective antagonist naltrindole also blocked the antihyperalgesic action of systemic loperamide (Shinoda, Hruby, & Porreca, 2007) . Furthermore, a recent study showed that the peripherally acting MOR opioid dermorphin attenuated pain after peripheral nerve injury, although repeated administration induced antiallodynic tolerance (Tiwari et al., 2018) . In accordance, the blockade of peripheral MOR by methyl-naltrexone dose dependently reduced the onset of morphine antinociceptive tolerance and morphine-induced hyperalgesia in uninjured and neuropathic pain conditions, without altering acute morphine antinociception (Corder et al., 2017) .
Many studies have examined the molecular mechanisms behind the decreased effectiveness of systemic morphine in neuropathic pain, focusing on spinal mechanisms. They include reduction in MOR expression in the spinal dorsal horn (Porreca et al., 1998) , enhanced spinal release of dynorphin (Bian et al., 1999; Nichols, Lopez, Ossipov, Bian, & Porreca, 1997) and cholecystokinin (CCK) (Nichols, Bian, Ossipov, Malan, & Porreca, 1996; Zhang, de Araujo Lucas, Elde, Wiesenfeld-Hallin, & Hökfelt, 2000) , increased NMDA activity and the subsequent intracellular activation of protein kinase C (PKC) and nitric oxide (NO) synthesis (Bian et al., 1999; Mao et al., 1995) , upregulated expression of spinal metabotropic glutamate receptor 1 (mGluR 1 ) (Fundytus et al., 2001 ) and activation of tonic descending facilitation pathways from the brain (Vanderah et al., 2001) . Alternatively, several peripheral dysregulations that operate after nerve lesion and may contribute to the reduction in systemic morphine potency have been also suggested. Drastic decrease of MOR expression in dorsal root ganglia (DRG) neurons due to primary afferent fibres damage was reported years ago (Li, Kaneko, & Mizuno, 1996; Obara et al., 2010; Ossipov et al., 1995b; Rashid et al., 2004; Zhang, Bao et al., 1998) . More recently, epigenetic alterations have been suggested to be responsible for this down-regulation of MOR gene expression in the DRG and in the dorsal horn of the spinal cord, leading to limited morphine effectiveness (Rivat, 2016; Uchida, Ma, & Ueda, 2010; Uchida, Matsushita, Araki, Mukae, & Ueda, 2015; Zhang et al., 2016) . Dysfunctional coupling of MOR to G protein in the DRG following nerve injury was also reported and related to the diminished analgesic efficacy of morphine in neuropathic pain (Obara et al., 2010) . Otherwise, the pronociceptive effects of spinally administered MOR agonists under neuropathic pain conditions were related to the release of substance P and/or excitatory amino acids (Chen, McRoberts, & Marvizón, 2014; Mauborgne, Lutz, Legrand, Hamon, & Cesselin, 1987) , or to the ability to inhibit presynaptic met-enkephalin release (Ueda, Fukushima, Kitao, Ge, & Takagi, 1986) .
It is noteworthy that preclinical data do not correlate well with clinical experience in neuropathic pain. Indeed, some severe neuropathic pain conditions are still treated by systemic MOR agonists, despite the important side effects. Thus, intrathecal opioids have been shown to be effective in some intractable clinical cases of non-cancer neuropathic pain, alone or in combination with other drugs (Martin Paiz et al., 2015; Sadiq & Poopatana, 2007; Vigneri et al., 2016; Warner, Watson, Bendel, & Moeschler, 2018; Wu, Huang, Chen, Huang, & Chou, 2013) . Several studies have also addressed the issue of whether peripheral opioid mechanisms are of significance in some clinical settings. Indeed, peripheral analgesia with morphine following localized injection was observed in arthritis pain (Stein, Yassouridis, Szopko, Helmke, & Stein, 1999) , in knee and dental surgery (Kalso, Smith, McQuay, & Andrew Moore, 2002; Likar et al., 2001) . Topical morphine was also effective when applied to painful ulcers and skin lesions (Ballas, 2002; Long et al., 2001 acting MOR antagonist, to neuropathic pain patients was safe and effective against opioid-induced constipation without affecting analgesia (Webster, Michna, Khan, Israel, & Harper, 2017; Webster & Israel, 2018) , suggesting a minimal role of peripheral MOR in opioid analgesia under such pain conditions. The differences between experimental and clinical data in the efficacy of opioid treatments raise the issue of the predictive value of preclinical studies. As shown in Table 1 , animal models of peripheral nerve injury have become the gold standard for the preclinical study of novel analgesics targeted at neuropathic pain. However, most of the clinical trials for neuropathic pain were carried out in patients without traumatic peripheral nerve injury, the main paradigm used in animal models (Rice et al., 2008) . Additionally, the "pre-injury" administration of the analgesic candidates that many rodent models use may be a serious concern, since it is not how analgesic compounds are currently used in clinical neuropathic pain (Lascelles, & Fleckwell, 2010) . Timing of lesions and of testing periods usually is much shorter in preclinical models than in human conditions, which may also be a critical aspect for their validity (Lascelles, & Fleckwell, 2010) . These limitations should be acknowledged for direct translation to human clinical trials. Using animals with a naturally occurring disease that is similar to the human condition would be a potentially useful and relevant approach to study the efficacy of analgesic compounds for a given clinical situation.
On the other hand, most tests used in preclinical pain evaluation are based on evoked withdrawal responses and, therefore, do not measure pain itself but the hyperactive reflexes that accompany pain (Table 2 ). These behaviours that respond to reflexes do not involve central integration (Matthies & Franklin, 1992) . Because conscious perception of pain was demonstrated to involve cortical structures in humans, the lack of involvement of cerebral cortex and reliance of reflex tests may account for the differential efficacy of pharmacological treatments in preclinical and clinical studies (Vierck, Hansson, & Yezierski, 2008) . In addition, the behavioural measures of evoked pain overlook the effect of analgesic compounds on continuous spontaneous pain, which is of high prevalence in patients with neuropathic pain. Models that provide better markers of more complex processing of nociceptive information, such as self-administration paradigms or conditioned place preference/aversion strategies, can be used to provide more clinically relevant results (Vierck et al., 2008) . Furthermore, measuring the affective dimension of animal pain would allow overcoming the fundamental mismatch between the subjective self-reports from patients and the approach used in preclinical pain research (Lascelles, & Fleckwell, 2010) .
| ROLE OF MOR IN THE

PATHOPHYSIOLOGY OF NEUROPATHIC PAIN
The abovementioned pharmacological studies allowed reviewing the contribution of MOR populations to the opioid-mediated analgesia in neuropathic pain. However, understanding the specific role of the MOR system in the pathophysiology of neuropathic pain requires the use of genetic tools. Knockout mice were certainly useful for the elucidation of the role of each component of the endogenous opioid system (receptors and peptide precursors) in inflammatory pain (reviewed in Maldonado, Baños, & Cabañero, 2018) . Similarly, studies investigating the function of DOR in neuropathic models using knockout mice agreed on a protective function of this receptor (Maldonado et al., 2018) . Nonetheless, the use of genetic approaches to clarify the participation of MOR in the development of neuropathic pain manifestations has generated apparently conflicting results. Thus, disruption of exon 2 or exon 2 and 3 of the Oprm1, the gene encoding MOR, resulted in reduced hypersensitivity to heat (Kögel, De Vry, Tzschentke, & Christoph, 2011) and cold stimuli (Maldonado, 2016) , without changes after mechanical stimulation in different models of neuropathy (Bohren et al., 2010) . A recent study with the same targeted exon 2 deletion of the Oprm1 gene reported no differences in heat, cold and mechanical hypersensitivity of mice with a partial ligation of the sciatic nerve (Roeckel et al., 2017) . A different knockout model targeting exon 1 showed no alteration of heat and cold hypersensitivity, but more prominent mechanical allodynia following unilateral nerve injury on L5 (Mansikka et al., 2004) . Knockout mice with a disruption of exon 11 showed the same mechanical hypersensitivity than wild-type animals in the spared nerve injury model (Wieskopf et al., 2014) . Table 3 summarizes the contribution of MOR to neuropathic pain-induced hypersensitivity considering different strategies of Oprm1 disruption and distinct neuropathic models. These divergent results could be explained by the heterogeneous MOR knockout and neuropathic pain models used in each study. However, they may also suggest a complex role for MOR in the pathophysiology of chronic neuropathic pain. Unchanged nociceptive manifestations observed in MOR knockouts compared to wild types could suggest limited participation of endogenous MOR activity modulating the expression of neuropathic pain-related hypersensitivity. This fact does not exclude the involvement of MOR in the analgesic activity of exogenous agonists in such abnormal pain conditions. Attenuated nerve injury-induced hypersensitivity observed in two studies (Kögel et al., 2011; Maldonado, 2016) may suggest a maladaptive function of MOR in neuropathic pain conditions. Therefore, pronociceptive effects of MOR in such circumstances should be considered. The novel genetic tools now available to modify specific neuronal populations in mice are already providing answers on the functioning of each component of the opioid system in other modalities of chronic pain (Gaveriaux-Ruff et al., 2011; Weibel et al., 2013) , and they will also facilitate the further elucidation of the specific role of each MOR subpopulation in neuropathic pain.
Despite the power of genetic technologies, several shortcomings need to be overcome to improve the relevance and translational transfer of knowledge gleaned from genetic models. A general issue that affects all animal studies including genetic models is the need for improving painful behavioural readouts, as described in the previous section (Handwerker & Arendt-Nielsen, 2013) . Other aspects that need to be considered are the differences and limitations of the currently used genetic backgrounds. Indeed, inbred mouse lines often used in genetic models do not mimic the diverse population in genetic terms of patients with neuropathic pain. Inserting an additional step in the drug discovery programme of candidate molecules over several mouse strains would be essential to verify that pharmacological modulation of one given mediator could yield widespread clinical utility (Handwerker & Arendt-Nielsen, 2013) . Genetically engineered mice have further limitations and being aware of them is crucial for an appropriate interpretation of the outcomes. Changes in the expression patterns of the target gene during developmental and postnatal stages, endogenous compensatory phenomena, widespread effects on the genome when using Cre recombinase expression, and harmful effects on the organism of tamoxifen, used to induce temporal-specific genome editing, are some of these restraints (Justice & Dhillon, 2016) .
| NEUROPATHOLOGICAL MECHANISMS SHARED BY NEUROPATHIC PAIN AND OPIOID TREATMENT
The reasons to explain the lower effectiveness of MOR agonists in neuropathic pain than in other types of severe chronic pain are still unclear. It is well known that opioid treatments are associated with the development of tolerance resulting from decreased MOR efficacy following repeated administration. Multiple adaptive changes occurring at the cellular level could T A B L E 3 Consequences of constitutive genetic MOR deletion in neuropathic pain-induced hypersensitivity explain opioid tolerance. One of them is the appearance of changes of MOR coupling to G proteins, leading to a "withinsystem" adaptation process (Ossipov et al., 2004) . However, opioid administration may also induce the activation of antiopioid/pronociceptive systems by MOR stimulation, triggering a "between-system" adaptation process. This pronociceptive effect may lead to opioid-induced hyperalgesia, which opposes the analgesic effect of an opioid agonist (Hayhurst & Durieux, 2016; Ossipov, Lai, King, Vanderah, & Porreca, 2005) . From a physiological viewpoint, the fact that stimulation of MOR triggers the development of a compensatory pronociceptive response agrees with the "opponent process theory," which postulates that drug effects are automatically opposed by centrally mediated mechanisms that contain the intensity of these drug effects (Koob, 1996) . Although tolerance can be overcome by increasing opioid dose, hyperalgesia is worsened in the long run by increasing the opioid administration. Since pain hypersensitivity is a common mechanism to both opioid tolerance and neuropathic pain, it would participate in the decreased antinociceptive efficacy of MOR agonists under these painful conditions, leading to an apparent tolerance. Alternatively, opioid treatment to individuals already suffering from neuropathic pain could aggravate their pathophysiological state by exacerbating the pain hypersensitivity, as illustrated in Figure 1 . The following sections describe neuroplastic changes that occur in the nervous system secondary to opioid exposure or nerve injury, which may contribute to the limited usefulness of opioids under neuropathic pain conditions (summarized in Figure 2 ). Although it was assumed that the development of tolerance took time following opioid administration, it was later shown F I G U R E 1 Following repeated opioid exposure, tolerance to the analgesic effects is developed leading to escalating dosages. Preclinical studies advocate for a cellular hypothesis or "within-system" adaptation process to explain opioid analgesic tolerance, based on changes of MOR coupling to G protein. Tolerance may also be the result of an activation of counteracting systems, that is, anti-opioid/pronociceptive systems, which oppose the net analgesic effect of an opioid agonist ("between-system" adaptation process) that may lead to opioid-induced hyperalgesia, not only analgesia. Therefore, tolerance can be operationally defined as a decrease in opioid effectiveness, but also as the result of a leftward shift in pain sensitivity. On the other hand, neuropathic pain is also characterized by pain hypersensitivity, which represents a common mechanism for both opioid tolerance and neuropathic pain. Nerve injury-induced pain hypersensitivity could explain the decreased antinociceptive efficacy of MOR agonists under neuropathic pain conditions resulting in an apparent tolerance. Alternatively, opioid treatment to individuals already suffering from neuropathic pain could aggravate their pathophysiological state by enhancing pain hypersensitivity that opioid tolerance can develop in a short time frame, possibly within hours when individuals are exposed to high doses of opioids with high intrinsic activity (Célèrier et al., 2000; Guignard et al., 2000) . This rapid tolerance was related to MOR agonists-mediated activation of pronociceptive systems, leading to pain amplification (Ghelardini, Di Cesare Mannelli, & Bianchi, 2015) . Several mechanisms contribute to the sensitization of pain facilitatory systems, which finally lead to opioid-induced hyperalgesia. These responses have been reported in some cases after the first dose, although the situation is usually aggravated following repeated administration (Angst & Clark, 2006; Vanderah et al., 2001) . Acute administration of MOR agonists induces long-term potentiation (LTP) of C-fibre synapse in the spinal cord dorsal horn by engaging MOR and NMDA receptors (Drdla, Gassner, Gingl, & Sandkühler, 2009; Heinl, Drdla-Schutting, Xanthos, & Sandkuhler, 2011) . Once MOR is activated, they trigger NO-mediated potentiation of NMDA receptors activity through the recruitment of PKC and G α subunits (Garzón, Rodríguez-Muñoz, & Sánchez-Blázquez, 2008; Rodríguez-Muñoz, Sánchez-Blázquez, Vicente-Sánchez, Berrocoso, & Garzón, 2012) . NMDA activation leads to a substantial rise of Ca 2+ , which directly correlates with LTP magnitude (Ikeda, Heinke, Ruscheweyh, & Sandkühler, 2003) . This intracellular Ca 2+ increase triggers several signal transduction pathways that contribute to C-fibre synapse LTP consolidation, including the activation of calcium-calmodulin-dependent protein kinase II, protein kinase A, phospholipase C, inositol triphosphate-3, NO synthase and members of the mitogenactivated protein kinase family (MAPK), such as extracellular signal-regulated kinase (Ikeda et al., 2003; Sandkühler, 2007; Willis, 2001) . Prostaglandins, like PGE 2 , can also stimulate glutamate release from astrocytes and from the spinal cord dorsal horn neurons with subsequent activation of the NMDA receptors (Bezzi et al., 1998) . In addition to NMDA-dependent pronociceptive systems, administration of opioids has been shown to induce the release of anti-opioid peptides in the central nervous system, which oppose analgesic effects leading to opioidinduced hyperalgesia and giving the appearance of tolerance to analgesic effects of opioids. Anti-opioid properties have been attributed to various neuropeptides, being the best studied CCK (Benoliel et al., 1991; Bourgoin et al., 1994; Zhou, Sun, Zhang, & Han, 1993) , neuropeptide FF (NPFF) (Elhabazi et al., 2012; Yang, Fratta, Majane, & Costa, 1985) and orphanin (FQ)/nociceptin (Gouardères, Tafani, Meunier, Jhamandas, & Zajac, 1999; Yuan, Han, Chang, & Han, 1999) . The blockade of anti-opioid receptors with selective antagonists of CCK (Dourish, Hawley, & Iversen, 1988; Maldonado, Derrien, Noble, & Roques, 1993) , NPFF (Bihel et al., 2015; Hammoud et al., 2018) and FQ/nociceptin (Rizzi et al., 2000) prevented opioid-induced hyperalgesia and enhanced opioid analgesic effects. Stimulation of NMDA receptors also induced a dose-dependent release of NPFF in spinal cord (Devillers & Simonnet, 1994) , suggesting the existence of close relationships between anti-opioid and NMDA systems for producing pain hypersensitivity associated with opioid treatment. Dynorphin, originally identified as an endogenous MOR ligand, can also act as an anti-opioid under certain conditions. The enhanced expression and pronociceptive actions of spinal dynorphin following sustained morphine exposure were related to opioid-induced hyperalgesia (Gardell et al., 2002) . Elevated expression of spinal dynorphin promoted the release of excitatory amino acids from primary afferent neurons (Faden, 1992; Skilling, Sun, Kurtz, & Larson, 1992) and stimulated the production of PGE 2 in the spinal cord (Koetzner, Hua, Lai, Porreca, & Yaksh, 2004) . Dynorphin also induced the release of other excitatory transmitters, such as substance P and calcitonin gene-related peptide from primary afferent fibres in spinal cord (Gardell et al., 2002) .
|
Supraspinal areas play an important role in opioidinduced pain hypersensitivity. Thus, two main cell subpopulations related to pain transmission have been reported in the RVM. OFF cells, which activation correlates with inhibition of nociceptive input, and ON-cell action that facilitates nociceptive transmission in the dorsal horn of the spinal cord (reviewed by Fields, 2004; Porreca, Ossipov, & Gebhart, 2002) . ON-cells send descending serotonergic projections that ultimately activate excitatory 5-HT 3 R and 5-HT 2 R in the spinal dorsal horn, enhancing C-fibre-evoked field potentials and increasing pain sensitivity (Barnes, Hales, Lummis, & Peters, 2009; Barnes & Sharp, 1999; Gerhold, Drdla-Schutting, Honsek, Forsthuber, & Sandkuhler, 2015; Heinl et al., 2011) . Descending facilitation of nociceptive transmission through activation of MOR located in the ON-cells of the RVM was reported following acute exposure to fentanyl, morphine and ultra-low dose of buprenorphine (Gerhold et al., 2015; Heinl et al., 2011; Vanderah et al., 2001) . In contrast, intrathecal administration of 5-HT 3 R antagonists has been shown to prevent the development of opioid-induced hyperalgesia (Liang, Li, & Clark, 2011; Vera-Portocarrero et al., 2007) . CCK-induced modulation of opioid antinociception was also reported at the supraspinal level. Thus, CCK in the RVM elicited opioid-induced hyperalgesia and subsequently reduced opioid antinociception Xie et al., 2005) , which was opposed by CCK antagonism in the same structure (Xie et al., 2005) . Although the circuitry is not fully understood, CCK may drive descending facilitation of pain by blocking opioid effects on RMV OFF cells (Heinricher, McGaraughty, & Tortorici, 2001) .
The enhancement of descending facilitation by ON/OFF cells following opioid treatments is well accepted in animal studies, although it has not been validated in humans due to the experimental approaches currently used in clinical studies. The function of endogenous descending pain inhibitory pathways is usually evaluated in humans by the conditioned pain modulation paradigm (CPM) (Nir & Yarnitsky, 2015) , using a variety of "pain inhibits pain" models, in which one conditioned noxious stimulus modulates another, the test stimulus, through descending pathways (Pud, Granovsky, & Yarnitsky, 2009 ). In healthy individuals, CPM is expressed by the reduced painfulness of the test stimulus induced by the application of the conditioning stimulus. However, less efficient CPM was observed in patients undergoing opioid treatments in various pain syndromes (Ram, Eisenberg, Haddad, & Pud, 2008) , suggesting altered descending inhibitory control of pain. Thus, low efficient CPM demonstrated the pronociceptive pain modulation profile of patients with opioid-induced hyperalgesia.
The hyperalgesic effects observed after acute opioid exposure were progressively enhanced after repeated administration (Célèrier et al., 2000; Célèrier, Laulin, Corcuff, Le Moal, & Simonnet, 2001) . Similarly, gradual and dosedependent pain hypersensitivity was displayed by rats during continuous infusion of morphine (Vanderah et al., 2001) . These findings suggest a time-related sensitization process of pain facilitating systems leading to long-lasting opioid-induced hyperalgesia. These changes occurring after opioid exposure produce central pain sensitization and increase the need for opioid analgesic medication. The existence of opioid-induced hyperalgesia, as an alternative explanation of acute opioid tolerance, has extensively been demonstrated in humans during withdrawal of short-term intraoperative infusion of opioids with high intrinsic activity (Angst, Koppert, Pahl, Clark, & Schmelz, 2003; Crawford, Hickey, Zaarour, Howard, & Naser, 2006; Kim et al., 2013) .
| Nerve injury-induced pain hypersensitivity
Similar mechanisms to those leading to opioid-induced pain hypersensitivity have been reported during the development of neuropathic pain, contributing to the reduced analgesic effect of MOR agonists in such conditions. Thus, LTP at C-fibre synapses in the superficial spinal dorsal horn was also reported in nerve-injured animals (Ikeda et al., 2003; Sandkühler, 2009) . As with opioid-induced LTP, activation of spinal NMDA receptors and the ensuing calcium-dependent neurochemical changes in the postsynaptic neurons are crucial for neuropathic pain-induced LTP of C-fibre (Sandkühler, 2009) . Additionally, the activation of spinal NK1 and group I metabotropic glutamate receptors (mGluR 1 and mGluR 5 ) and the opening of T-type voltage-gated calcium channels have been reported to further contribute to C-fibre synapses LTP in neuropathic pain conditions (Sandkühler, 2007) . As with opioid exposure, nerve injury increased the levels of spinal dynorphin leading to the enhancement of excitatory transmitters release and the modulation of NMDA receptors (Bian et al., 1999; Mao et al., 1995) . The activation of spinal bradykinin receptors by elevated spinal dynorphin has been correlated with maintenance of neuropathic pain-induced hypersensitivity (Bannister et al., 2014) . Spinal prostaglandins F I G U R E 2 Neuroplastic changes shared by sustained opioid exposure and neuropathic pain at the level of the rostral ventromedial medulla (RVM) (a) and superficial spinal dorsal horn synapses (b). (a) Fentanyl, morphine and ultra-low dose of buprenorphine enhance synaptic transmission at C-fibres by the triggering of descending facilitation via activation of mu-opioid receptor (MOR) located in the ON-cells of the RVM. This phenomenon has an immediate onset during acute drug administration and get aggravated with repeated dosing. Increased CCK has been shown under chronic pain conditions and after long-term opioid treatment and would account for an increased descending serotonergic facilitation from the RVM. (b) Opioid exposure and neuropathic pain also lead to pain hypersensitivity by inducing LTP at C-fibre synapses. While morphine and fentanyl-induced LTP requires presynaptic MOR and NMDA activation, remifentanil and nerve injury-induced LTP act via activation of postsynaptic MOR and NDMA. Serotonin released from facilitatory descending projections acts on pre-and postsynaptic 5-HT 3 R, but it can also act on astrocytic 5-HT 2 R contributing to glial activation. Both enhanced transmitter release and enhanced transmitter effect lead to substantial rise of postsynaptic Ca 2+ , which triggers Ca 2+ -dependent signal transduction pathways (activation of PKA, PKC, CamKII, ERK, NOS) and consolidate LTP. Increased levels of dynorphin is another neurochemical change that contribute to LTP at C-fibres and have been observed in nerve-injured and long-opioid exposed animals. Dynorphin modulates NMDA activity and promotes further release of excitatory amino acids and neuropeptides (SP, CGRP) from presynaptic terminals. Opioid administration also induces the release of anti-opioid peptides (CCK, NPFF, FQ/nociceptin) in the spinal cord, and their pronociceptive activity opposes the antinociceptive effects of opioids. Decreased expression of delta-opioid receptors in the dorsal root ganglia was observed after remifentanil systemic infusion and proposed as another underlying mechanism for delayed pronociceptive effect of remifentanil. Opioids can also induce glial reactivity by acting on microglial TLR4 and astrocytic MOR, which leads to the release of pro-inflammatory mediators (cytokines, PGE2), thus promoting the initiation of neuroinflammation. Glial activation and neuroinflammation are well-known pathophysiological mechanisms underlying neuropathic pain, which further support that both conditions are modulating each other. were also proposed to be important in the early pathogenesis of experimental neuropathic pain (O'Rielly & Loomis, 2006) .
Increased activity of RVM ON-cell neurons and serotonergic descending facilitation have also been demonstrated to promote pain in experimental models of neuropathy (reviewed by Ossipov et al., 2010; Porreca et al., 2002) . Spinal 5-HT 3 R and 5-HT 2 R are activated by descending serotonergic pathways from the RVM after peripheral nerve injury, which facilitate transmission at spinal dorsal horn synapses resulting in hyperalgesia and allodynia (Aira et al., 2010; Dogrul, Ossipov, & Porreca, 2009 ). RVM neurons co-expressing MOR and CCK 2 receptors, which in contrast to MOR facilitate pain transmission, were proposed to be critical for neuropathic pain maintenance (Zhang et al., 2009) . Surgical disruption of the ipsilateral dorsolateral funiculus, the spinal tract containing descending pathways from the RVM, abolished nerve injury-induced thermal allodynia in rats (Ossipov, Hong Sun, Malan, Lai, & Porreca, 2000) . Altered descending inhibition of pain has also been demonstrated in patients with neuropathic pain syndromes, as shown by less efficient CPM compared to healthy controls (Nahman-Averbuch et al., 2011; Tuveson, Leffler, & Hansson, 2007 , 2009 , and CPM is reliably used in the clinical practice as a predictor for the development of neuropathic pain (Granovsky, 2013) .
| Additive effects of opioid exposure and neuropathic pain on pain hypersensitivity
The analgesic effect of opioid agonists in neuropathic pain and other pain conditions is the sum of two opposing processes on pain perception from the early exposure to the drug. Since the nociceptive sensitization processes triggered by the first opioid administration are already present in neuropathic pain, opioid therapy may be ineffective from the beginning. The repeated opioid exposure can even aggravate the neuropathic pain syndrome by potentiating the activation of pronociceptive systems and enhancing pain hypersensitivity. This common pain hypersensitivity phenomenon occurring during neuropathic pain and opioid exposure could be the mainstay for the reduced analgesic effect of opioids in neuropathic pain.
Several studies have demonstrated the involvement of enhanced spinal NMDA activity in the loss of antinociceptive efficacy of morphine in nerve-injured animals, since NMDA antagonists prevented not only the development of hypersensitivity, but also the loss of antiallodynic efficacy of intrathecal morphine (Bian et al., 1999; Gupta, Gupta, & Tripathi, 2011; Mao et al., 1995; Ossipov et al., 1995b) . Patients receiving NMDA antagonists, such as ketamine, alongside opioids have also exhibited recovery of opioid analgesic effect (da Cunha Leal, Clivatti, Garcia, & Sakata, 2010; Lee, Song, Jeong, & Park, 2011; Pasero & McCaffery, 2012) . Other proposals have also been suggested to oppose the activation of pronociceptive systems and/or to block the sensitization processes induced by MOR activation. Nitrous oxide, a widely used inhalation anaesthetic, has been shown to be an effective NMDA antagonist (Jevtović-Todorović et al., 1998) . The exposure to nitrous oxide during surgical procedures reduced in a dose-dependent manner opioid-induced hyperalgesia in rats (Richebé et al., 2005) and humans (Echevarría et al., 2011) . The efficacy of gabapentinoids in mitigating opioid-induced hyperalgesia has been demonstrated in animal models and some human case studies (Compton, Kehoe, Sinha, Torrington, & Ling, 2010; Cuignet, Pirson, Soudon, & Zizi, 2007; Ishida, Nikai, Hashimoto, Tsumori, & Saito, 2012; Jo et al., 2011; . Similarly, cyclooxygenase inhibitors were found to effectively attenuated opioid-induced hyperalgesia in animals (Li et al., 2018) and humans (Lenz et al., 2011; Tröster et al., 2006) by antagonizing NMDA receptor activation. Dexmedetomidine, a selective α 2 -adrenergic agonist, also reduced opioid-induced hyperalgesia in rats (Yuan et al., 2017; Zheng et al., 2012) and humans by potentiating noradrenergic inhibition in the spinal cord. Nefopam, a monoamine reuptake inhibitor, successfully opposed the hyperalgesic effects of opioids in humans (Choi et al., 2016; Kim et al., 2017) . These results suggest the clinical interest of using drugs that modulate the activity of NMDA receptors and monoamine system to disrupt sensitization processes underlying pain hypersensitivity, and consequently restoring the analgesic efficacy of opioid agonists under neuropathic pain conditions.
Interestingly, an important component of central pain sensitization processes triggered by opioid administration and nerve injury occurs in the spinal cord dorsal horn, leading to the loss of spinal antinociceptive actions of opioid agonists.
| Decreased MOR-mediated antinociceptive efficacy: change of MOR coupling to G protein
Conversely to opioid-induced hyperalgesia, tolerance is generally believed to occur over a period of days or weeks of repeated or sustained administration of opioids, and is associated to an adaptive response within the same system that progressively neutralize the drug effect (Simonnet & Rivat, 2003) . Early in vitro studies suggested down-regulation of MOR as a mechanism to explain the reduced antinociceptive efficacy of opioids following repeated administration (Law, Hom, & Loh, 1982 , 1983 , although this down-regulation was not clearly replicated when using in vivo studies (Rothman et al., 1989) . A more accepted view held that tolerance is more closely related to desensitization processes, involving altered coupling of MOR to intracellular signalling via G proteins. Interestingly, neuropathic pain and long-term opioid treatment are both associated with molecular changes in signalling pathways triggered by MOR. In such conditions, MOR coupling with the inhibitory G αi or G αo protein decreases and shifts to the excitatory G αs protein (Tsai et al., 2009; Wang, Friedman, Olmstead, & Burns, 2005) . This shift decreases the ability of morphine to acutely inhibit adenylate cyclase during chronic treatment (Liu, Gong, & Qin, 1999; Puttfarcken, Werling, & Cox, 1988) . Indeed, MOR stimulation by endogenous peptides or exogenous agonists may result in excitatory effects leading to increased cAMP, CREB phosphorylation and altered association of multiple signalling proteins (Bohn, Gainetdinov, Lin, Lefkowitz, & Caron, 2000; Christie, 2008; Wang, Burns, & Koch, 2009; Zhang, Ferguson et al., 1998) . Ultra-low doses of MOR antagonists target a pentapeptide region in c-terminal filamin A, which binds to MOR after morphine stimulation, and is essential for MOR G αi/o -to-G αs switch (Wang, Frankfurt, Burns, Carlen, & Velazquez, 2008; Wang et al., 2009 ). Thus, ultra-low dose of naloxone or naltrexone can prevent the excitatory switch of MOR coupling, attenuating the development of morphine tolerance and restoring morphine analgesia (Crain & Shen, 1995 Shen & Crain, 1997; Tsai et al., 2009; Wang et al., 2005) . Similar results were described with oxycodone in combination with ultra-low dose of naltrexone (LargentMilnes, Guo, Wang, Burns, & Vanderah, 2008) . Since these adaptive changes promoting morphine tolerance after longterm opioid treatment are also present under neuropathic pain conditions, they may accelerate the onset of opioid tolerance development in such conditions.
| Initiation of neuroinflammation: TLR4 and glial reactivity
Another mechanism that neuropathic pain and long-term opioid treatment share is the induction of central glial reactivity. The role of central glial cells in modulating opioid pharmacological responses has recently emerged (Trang et al., 2015) . Contrary to that previously accepted, opioid action seems not restricted to neuronal opioid receptors and can also act on glial cells. Glial cells express MOR and stimulation of this MOR population activates microglia (Ferrini et al., 2013) . However, other studies suggest the lack of MOR expression in spinal microglia (Corder et al., 2017; Kao et al., 2013) . Morphine has also been suggested to activate Toll-like receptor 4 (TLR4) and MD-2 signalling in microglia (Hutchinson et al., 2007; Hutchinson et al., 2010; Watkins, Hutchinson, Rice, & Maier, 2009 ). Toll-like receptors (TLRs) are widely expressed in different components of the nervous system and play a key role in the recognition of the pathogen-associated molecular patterns expressed by microorganisms and the initiation of innate immunity. TLR4 is particularly abundant in microglia and was shown to participate in triggering microglial reactivity (Lee, Lee, Cho, & Lee, 2013) and pro-inflammatory cytokines production (IL-1β, IL-18, TNFα) in a p38 MAPKdependent manner . Opioid agonists also activate astrocytes probably by acting on MOR present in these cells, inducing the release of proinflammatory cytokines (IL-1β) and chemokines (CCL2) that alter glutamate buffering, leading to hyperexcitable neurons (Deleo, Tanga, & Tawfik, 2004) . The opioid-induced glial reactivity and the subsequent release of pro-inflammatory mediators may counteract analgesic effect and potentiate pronociceptive effect of opioids Hutchinson, Northcutt et al., 2008; Johnston et al., 2004) . In agreement, blockade of opioid-induced glial activation by glial inhibitors potentiates spinal morphine analgesia and attenuates the development of opioid-induced hyperalgesia in animal studies (Hutchinson et al., 2007; Hutchinson, Northcutt et al., 2008; Raghavendra, Tanga, & Deleo, 2004; Song & Zhao, 2001; Watkins et al., 2009) . Specific antagonism of TLR4 or the pro-inflammatory mediator receptor IL-1R similarly results in enhanced opioid analgesia and reduced opioid-induced hyperalgesia in rodents (Hutchinson et al., 2007; Johnston et al., 2004) . However, opioid-induced hyperalgesia and tolerance were not modified in TLR4 knockout mice suggesting that the effect of chronic opioid administration on microglial activation is not mediated by TLR4 (Fukagawa, Koyama, Kakuyama, & Fukuda, 2013; Mattioli et al., 2014) . Opposing the glial hypothesis, a recent study showed that peripheral MOR but not microglial MOR underlies morphine tolerance (Corder et al., 2017) . Therefore, the effects of chronic opioid exposure on microglial activation and the possible mechanisms involved are still controversial.
The opioid-induced glial activation could be particularly relevant under conditions of neuropathic pain since it already entails glial reactivity and TLR4 activation. Therefore, neuropathic pain treatment with opioids may produce additive effects on glial activation, which would aggravate neuropathic pain manifestations and reduce the analgesic efficacy of opioids, as it has been already reported (Raghavendra, Rutkowski, and DeLeo (2002) . Indeed, spinal inhibition of pro-inflammatory cytokines in rats attenuated nerve injuryinduced pain manifestations, improved the effectiveness of morphine and reduced the development of tolerance and morphine-induced hyperalgesia under neuropathic pain conditions (Raghavendra et al., 2002) . Similar results were obtained with the administration of the glial modulating agent propentofylline in rats, which decreased glial reactive phenotypes and glial release of damaging pro-inflammatory factors, and enhanced the glutamate clearance by astrocytes (Raghavendra, Tanga, Rutkowski, & DeLeo, 2003; Sweitzer & De Leo, 2011) . These preclinical findings suggest the interest of combined therapies with morphine and glial
modulators or antagonists of pro-inflammatory cytokines for the treatment of neuropathic pain. However, results from clinical studies evaluating glial modulators in neuropathic pain patients have not been very promising. Thus, propentofylline failed to decrease pain in post-herpetic neuralgia patients (Landry, Jacobs, Romero-Sandoval, & DeLeo, 2012) . Minocycline, another inhibitor of glial activation, was not effective either for preventing neuropathic pain after lumbar discectomy (Martinez et al., 2013) . Losmapimod, a p38 kinase inhibitor, could not be differentiated from placebo in terms of analgesia in patients with neuropathic pain from peripheral nerve injury or lumbosacral radiculopathy (Ostenfeld et al., 2013 (Ostenfeld et al., , 2015 . In contrast, a clinical trial with the p38 MAP kinase inhibitor dilmapimod revealed moderate analgesic effects in neuropathic pain following nerve injury (Anand et al., 2011) . Functional differences between rodent and human microglia and macrophages have been proposed to explain the absence of analgesic effects of propentofylline and other glial-targeted agents in neuropathic pain patients (Landry et al., 2012) . Indeed, human microglia is less responsive to lipopolysaccharide stimulation and propentofylline treatment than the homolog rodent cells (Landry et al., 2012) . These findings reveal that functional differences between species must be considered for a better translational transfer of knowledge from preclinical studies to clinical practice.
Preclinical studies also provided evidence for the potential efficacy of low-dose of MOR antagonists in neuropathic pain. Thereby, intrathecal and systemic administration of ultra-low dose of dextro (inactive) and levo (active) stereoisomers of naltrexone and naloxone were also able to reverse neuropathic pain by inhibiting TLR4 signalling Lewis et al., 2012) . This neuropathic pain reversal correlates with decreased microglial activation induced by this dose of dextro naltrexone . Moreover, ultra-low dose of dextro naloxone prevented the down-regulation of Na + /K + -ATPase induced by lipopolysaccharide and the inflammatory responses in astrocytes in primary culture (Forshammar, Block, Lundborg, Biber, & Hansson, 2011) , being both alterations present in neuropathic pain states. Among all the opioid antagonists showing protective properties, the stereoisomer dextro naloxone is of particular relevance for neuropathic pain treatment, since it is inactive in the neuronal opioid receptors that produce analgesia.
| CONCLUSION
Neuropathic pain is a clinical entity resistant to standard analgesic treatments and often insensitive to opioids. An important aspect to consider when evaluating analgesic efficacy of opioids on neuropathic pain is the route of administration. Preclinical studies have shown higher opioid potency at the supraspinal level, inefficacy of intrathecal opioids and controversial role of peripheral MOR under neuropathic pain conditions. However, intrathecal opioids have been shown to be effective in some clinical neuropathic pain states alone or combined with other drugs. Moreover, opioid administration and neuropathic pain share neuropathological mechanisms that can modulate each other, which may account for the low opioid analgesic efficacy in these clinical conditions. Pain hypersensitivity, namely by potentiated C-fibre transmission and descending facilitation, results from both acute opioid exposure and injury in the somatosensory system, which may explain the absence of opioid treatment effectiveness in neuropathic pain. Promotion of glial reactivity and neuroinflammation are common consequences of both sustained opioid administration and neuropathic pain and may contribute to the aggravation of pain hypersensitivity. However, controversial results have been reported and the precise role of glial cells on opioid responses remains to be further clarified. Molecular changes in signalling pathways triggered by MOR are also induced by chronic opioids and neuropathic pain, which support the accelerated onset of opioid tolerance development in such conditions. Therapeutic strategies targeting the mechanisms underlying these common alterations might reduce pain hypersensitivity and potentiate the analgesic effect of opioids in neuropathic pain. Thus, NMDA antagonists, nitrous oxide, gabapentinoids, α 2 -agonists and monoamine reuptake inhibitors are some therapeutic proposals reported to effectively oppose the activation of pronociceptive systems induced by MOR activation, enhancing the analgesic effect of opioids under neuropathic pain conditions when given in combination. The blockade of spinal glial activation by glial inhibitors or specific antagonism of TLR4 or IL-1R has been shown to attenuate opioid and nerve injury-induced hyperalgesia while potentiating opioid analgesia in animal models, but not in humans. Interestingly, ultra-low doses of MOR antagonists can enhance the analgesic efficacy of MOR agonists when co-administered under neuropathic pain conditions. Therefore, all these preclinical and clinical data suggest that opioid monotherapy may have low benefit in neuropathic pain. Thus, combination of opioid agonists with drugs targeted to block the sensitization processes induced by pharmacological MOR stimulation could be a promising therapeutic approach to optimize opioid analgesia under these neuropathic pain conditions.
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